{"organizations": [], "uuid": "f6792ca04041f1ce48f1f40e650210e79d32272c", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.bio-medicine.org", "main_image": "", "site_section": "http://feeds.bio-medicine.org/latest-medical-technology", "section_title": "Latest Medical Technology from Bio-Medicine.Org", "url": "http://www.bio-medicine.org/medicine-technology-1/Edison-Initiates-Coverage-on-Photocure-48363-1/", "country": "US", "title": "Edison Initiates Coverage on Photocure", "performance_score": 0, "site": "bio-medicine.org", "participants_count": 0, "title_full": "Edison Initiates Coverage on Photocure", "spam_score": 0.0, "site_type": "news", "published": "2015-09-25T20:26:00.000+03:00", "replies_count": 0, "uuid": "f6792ca04041f1ce48f1f40e650210e79d32272c"}, "author": "", "url": "http://www.bio-medicine.org/medicine-technology-1/Edison-Initiates-Coverage-on-Photocure-48363-1/", "ord_in_thread": 0, "title": "Edison Initiates Coverage on Photocure", "locations": ["LONDON"], "entities": {"persons": [], "locations": [], "organizations": []}, "highlightText": "", "language": "english", "persons": ["Edison"], "text": "RSS Navigation Links HOME >> MEDICINE >> TECHNOLOGY Edison Initiates Coverage on Photocure ... LONDON September 25 2015 /-/...Highlights of the analysis on Photocure by Edison's healthcare analyst...Photocure specialises in photodynamic therapy. Its bladder cancer imag... (Logo: http://photos.prnewswire.com/prnh/2013... Date:9/25/2015 \nLONDON , September 25, 2015 /PRNewswire/ -- \nHighlights of the analysis on Photocure by Edison's healthcare analysts Maxim Jacobs and Christian Glennie include: \nPhotocure specialises in photodynamic therapy. Its bladder cancer imaging product is sold as Hexvix in Europe and Cysview in the US. Photocure handles the marketing in Nordic countries and the US, while Ipsen is its marketing partner in the EU. Cevira is a Phase III-ready product for HPV-related diseases of the cervix and Visonac is a Phase III-ready product for acne. \n(Logo: http://photos.prnewswire.com/prnh/20130417/608168) \nWe value Photocure at NOK1,523m or NOK71 per basic share (NOK67 per diluted share). Upcoming catalysts will be the commencement of enrollment for the Phase III for Hexvix/Cysview to expand into the surveillance market and potential partnerships for both Visonac and Cevira. \nTo download this report, please click here . \nAll reports published by Edison are available to download free of charge from its website http://www.edisongroup.com . \nAbout Edison: Edison, the investment intelligence firm, is the future of investor interaction with corporates. Our team of over 100 analysts and investment professionals works with leading companies, fund managers and investment banks worldwide to support their capital markets activities. We provide services to more than 400 retained corporate and investor clients from our offices in London , New York , Frankfurt , Sydney and Wellington . '/>\"/> * Comment: * Email: (Date:9/24/2015)... ResMed Inc. (NYSE: RMD ) today announced it ... on Thursday, October 22, 2015, after the New York Stock ... be issued after 1:00 p.m. US Pacific Time and the ... future outlook. The earnings call is scheduled to ... webcast of the call can be accessed on ResMed,s Investor ... (Date:9/24/2015)... , Sept. 24, 2015 Mylan N.V. (NASDAQ: MYL ... Israel today is entirely without merit and that ... and proper in all respects. With that said, ... retail, including those in Israel—have always been free to switch ... Exchange (TASE) to the New York Stock Exchange (\"NYSE\"), through ... (Date:9/24/2015)... 2015 Cogmedix, a wholly owned subsidiary ... experience record sales growth as the 2015 calendar ... trusted provider of turnkey medical device manufacturing ... of medical and dental equipment innovators. In the ... production and increased demand from multiple medical device ... [ 0 ] ResMed to Announce First Quarter Fiscal Year 2016 Results [ 0 ] Mylan Comments on Meritless Perrigo Lawsuit Filed Today in Israel [ 0 ] Laser, Robotic, Optical and Diagnostic Medical Device Manufacturing Drive Steady Growth at Cogmedix ... 2012   announced its ... Financial Results Adjusted diluted EPS of ... for the same prior year period, an increase of 18%; ... 31, 2011 compared to $1.61 for the prior year, an increase of ... ... CITY, N.J., Feb. 21, 2012 S1 Pharmaceuticals, Inc. ... New Drug (IND) application to the U.S. Food and ... (Lorexys). Lorexys is the Company,s lead drug candidate for ... Female Sexual Dysfunction (FSD). Lorexys, clinical ... Mylan Reports Adjusted Diluted EPS of $0.53 for the Quarter, an 18% Increase Over Prior Year Quarter; and $2.04 for the Year, a 27% Increase Over Prior Year S1 Pharmaceuticals Announces IND Filing of SIP-104 (Lorexys) for the Treatment of Hypoactive Sexual Desire Disorder (HSDD) (Date:9/25/2015)... Va. and WASHINGTON, D.C. (PRWEB) , ... September ... ... Interchange (WEDI), the nation’s leading nonprofit authority on the use of health ... for Trusted Exchange (NATE), the nation’s leading nonprofit authority in consumer-mediated electronic   American Insurance Agencies, a ... of St. Louis, is announcing a joint charity effort with non-profit Whole Kids ... and pregnant women that reside in south central Missouri. , Whole Kids Outreach   ... health   a successful open-enrollment period, ... “Open   and Brokers Win on ... (Date:9/25/2015)... ... 25, 2015 , ... Millionaire Matchmaker Online states ... or attractive singles. Successful, rich, gorgeous, or attractive singles are welcome to join. People ... that someone may be looking for a \"sugar daddy\" or “sugar mommy”)? ... (Date:9/25/2015)... ,   Remote Media ... a look at the latest and coolest applications on the market for iOS, Android, ... review and shared with viewers how this application allows users to access files on ... [ 0 ] WEDI and National Association for Trusted Exchange (NATE) Announce Partnership [ 0 ] American Insurance Agencies and Non-Profit Whole Kids Outreach Launch Joint Charity Drive to Support Local Underprivileged Families   MillionaireMatchmakerOnline.net Shares Advice and Tips to Avoid Gold Diggers [ 0 ] Access Files on Network Devices with Remote Media Manager ... country join forces to advocate for more research funding ... we continue to mark Food Allergy Awareness Week, Robert ... of the Food Allergy Initiative (FAI), announced the formation ... are to help build a strong nationwide presence for ... ... 14 If the H1N1 pandemic flu follows the pattern ... more vigor in a second wave next fall. In 1918, ... rapidity, resulting in 3 explosive pandemic waves within a year,s ... the Prudent Use of Antibiotics and Microbiology Lab Director at ... ... life over 8 years of follow-up, study finds, , , ... extend heart patients, lives even eight years after implantation, ... presented Thursday at the Heart Rhythm Society annual meeting, ... therapy, sustained for over eight years, does in fact ... ... February 2009, the Office of the Vice President ... approximately $242,000 through its Collaborative Research Seed Grant ... (TRAC). The programs help UTSA faculty establish ... one or more of UTSA,s five strategic areas ... ... 14 Diabetes experts ... prediabetes, a condition affecting 57 million Americans, at ... Annual Meeting & Clinical Congress. These clinical ... medication. (Logo: ... ... HOUSTON, May 14 A free resource designed ... their diabetes was revealed today at the American ... & Clinical Congress.(Logo: http://www.newscom.com/cgi-bin/prnh/20090324/DC88061LOGO-b ... is a patient-friendly quarterly publication published by ... Robert F. Kennedy, Jr. Announces New Food Allergy Initiative Advocacy Steering Committee H1N1 Pandemic Precautions for Front Line Workers Implanted Defibrillators Boost Long-Term Survival UTSA announces funding for new faculty research New Clinical Recommendations for Treating America's Largest Healthcare Epidemic Diabetes Experts Partner With Novo Nordisk to Provide New Patient Materials ... produced in the adrenal gland and gonads, ... and estrone, both of which may be ... weak androgenic activity, estimated at ~(less than ... However, serum androstenedione levels often exceed testosterone ... ... Insulin-like growth factor II (IGF-II) is a ... the liver and is postulated to have mitogenic ... actions of IGF-II are mediated by binding to ... to the Type II IGF receptor, a monomeric ... ... Pregnancy-associated plasma protein A (PAPP-A) is ... is produced in high concentrations by ... into the maternal circulation in increasing ... PAPP-A is not specific to pregnancy ... ACTIVATED CLOTTING TIME SYSTEM...", "external_links": [], "published": "2015-09-25T20:26:00.000+03:00", "crawled": "2015-09-25T20:50:03.509+03:00", "highlightTitle": ""}